VERTEX PHARMACEUTICALS INC / MA Restricted Cash and Cash Equivalents
VERTEX PHARMACEUTICALS INC / MA (VRTX) had Restricted Cash and Cash Equivalents of $10.60 million as of 2026-06-30, per its 10-Q filed 2026-08-04.
Financial Statements › Balance Sheet › Assets
us-gaap:RestrictedCashAndCashEquivalents · last filed 2026-08-04
- 2026-06-30: Restricted Cash and Cash Equivalents $10.60M.
- 2026-03-31: Restricted Cash and Cash Equivalents $12.00M.
- 2025-12-31: Restricted Cash and Cash Equivalents $3.00M.
- 2025-09-30: Restricted Cash and Cash Equivalents $8.20M.
| Period end | Restricted Cash and Cash Equivalents |
|---|---|
| 2026-06-30 | $10.60M 10-Q · filed 2026-08-04 |
| 2026-03-31 | $12.00M 10-Q · filed 2026-05-05 |
| 2025-12-31 | $3.00M 10-Q · filed 2026-08-04 |
| 2025-09-30 | $8.20M 10-Q · filed 2025-11-04 |
| 2025-06-30 | $9.80M 10-Q · filed 2026-08-04 |
| 2025-03-31 | $10.70M 10-Q · filed 2026-05-05 |
| 2024-12-31 | $2.60M 10-Q · filed 2026-08-04 |
| 2024-09-30 | $8.90M 10-Q · filed 2025-11-04 |
| 2024-06-30 | $10.90M 10-Q · filed 2025-08-05 |
| 2024-03-31 | $11.40M 10-Q · filed 2025-05-06 |
| 2023-12-31 | $3.20M 10-K · filed 2026-02-13 |
| 2023-09-30 | $6.40M 10-Q · filed 2024-11-05 |
| 2023-06-30 | $2.30M 10-Q · filed 2024-08-02 |
| 2023-03-31 | $5.70M 10-Q · filed 2024-05-07 |
| 2022-12-31 | $8.00M 10-K · filed 2026-02-13 |
| 2022-09-30 | $5.50M 10-Q · filed 2023-11-07 |
| 2022-06-30 | $1.90M 10-Q · filed 2023-08-02 |
| 2022-03-31 | $3.90M 10-Q · filed 2023-05-02 |
| 2021-12-31 | $5.10M 10-K · filed 2025-02-13 |
| 2021-09-30 | $4.50M 10-Q · filed 2022-10-28 |
| 2020-12-31 | $700.00K 10-K · filed 2024-02-15 |
| 2016-09-30 | $21.90M 10-Q · filed 2016-10-31 |
| 2016-06-30 | $21.90M 10-Q · filed 2016-08-01 |
| 2016-03-31 | $21.90M 10-Q · filed 2016-05-03 |
| 2015-09-30 | $21.90M 10-Q · filed 2015-10-30 |
| 2015-06-30 | $21.90M 10-Q · filed 2015-08-04 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |